Royal Philips

2022 is starting on a worrisome note; patience warranted

13/01/22 -"While the fundamental metrics (i.e. DCF and NAV) continue to point to healthy upside potential (taking into consideration the long-term virtues of Philips’ offerings), the near-term is fraught with ..."

PDF page sample
Pages
68
Language
English
Published on
13/01/22
Download
You may also be interested by these reports :
24/01/22
Sartorius (Reduce, Germany), the Germany-based manufacturer of bioprocessing and lab equipment, is a high-quality asset, validated by its 30%+ ROE ...
20/01/22
Despite the continuation of a healthy recovery in the operating performance, our cautious stance on the stock is maintained. This is a function of ...
18/01/22
While Qiagen remains an attractive long-term testing bet, our performance estimates have been normalised considering the Omicron-induced risks for ...
13/01/22
While the fundamental metrics (i.e. DCF and NAV) continue to point to healthy upside potential (taking into consideration the long-term virtues of ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO